Tumor stage

Non metastatic tumor n = 108 (84.5%)

Metastatic tumor at presentation n = 20 (15.5%)

Total (n = 128) (%)

Age in years

less than 40

34 (31.5)

8 (40.0)

42 (32.8)

40 to 60

63 (58.3)

12 (60.0)

75 (58.6)

More than 60

11 (10.2)

0

11 (8.6)

Menopausal s

Premenopausal

73 (67.6)

18 (90.0)

91 (71.1)

Postmenopausal

35 (32.4)

2 (10.0)

37 (28.9)

BMI

Less than 25

8 (7.4)

2 (10.0)

10 (7.8)

25 to <30

57 (52.8)

10 (50.0)

67 (52.3)

30 or more

43 (39.8)

8 (40.0)

51 (39.8)

Tumor size

T1

10 (9.3)

0

10 (7.8)

T2

54 (50.0)

5 (25.0)

59 (46.1)

T3

35 (32.4)

6 (30.0)

41 (32.0)

T4

9 (8.3)

9 (45.0)

18 (14.1)

Lymph node

N0

20 (18.5)

0

23 (18.1)

N1

55 (50.9)

14 (73.7)

67 (52.8)

N2

30 (27.8)

5 (26.3)

34 (26.7)

N3

3 (2.8)

1 (5.0)

4 (3.1)

Stage

I

7 (5.5%)

IV = 20

(15.5%)

II

44 (34.4%)

II

57 (44.6%)

LVI

Yes

104 (69.3)

20 (100)

124 (96.9)

No

4 (3.7)

0

4 (3.1)

K1 67

Not done

21 (19.4)

4 (20.0)

25 (19.5)

less than 20

44 (50.6)

2 (12.5)

46 (35.9)

More than 20

43 (49.4)

14 (87.5)

57 (44.6)

Tumor grade

I

1 (0.9)

0

1 (0.8)

II

41 (38.0)

7 (35.0)

48 (37.5)

III

66 (61.1)

13 (65.0)

79 (61.7)

Histopathology

IDC

94 (87.1)

13 (65.0)

107 (83.6)

ILC

8 (7.4)

1 (5.0)

9 (7.0)

Others

6 (5.5)

6 (30.0)

12 (9.4)

Surgery

MRM

71 (65.7)

0

BCS

37 (34.3)

0

ALND

100 (92.6)

0

SLN

8 (7.4)

0

Neo adjuvant chemotherapy

34/108 (31.5%)

CR

6 (17.6%)

PR

24 (70.6%)

No response

4 (11.8%)

Types of chemotherapy

FAC

14 (12.9%)

14 (11%)

AC and Taxol

94 (87%)

20 (100%)

114 (89%)

Platinum/Gem

0 (0%)

20 (100%)

20 (15.6%)

Taxotere

0 (0%)

12 (60%)

Xeloda

0 (0%)

6 (30%)

Adjuvant XRT

NO

10 (9.3%)

20 (100%)

30 (23.4%)

conventional

56 (51.8%)

0

56 (43.8%)

hypofractionation

42 (38.9%)

0

42 (32.8%)